Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus

Published 2015 View Full Article

Authors

Keywords

NCT00985426, Hepatitis B vaccine, Toll-like receptor 9, Type 2 diabetes, CKD

Journal

VACCINE

Volume 33, Issue 7, Pages 833-837

Publisher

Elsevier BV

Online

2015-01-06

DOI

10.1016/j.vaccine.2014.12.060

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started